Cite
HARVARD Citation
Haas, N. et al. (n.d.). Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial. Journal for immunotherapy of cancer. p. . [Online].